Adjunctive perampanel for glioma-associated epilepsy.

Journal Article

Glioma-associated epilepsy is associated with excessive glutamate signaling. We hypothesized that perampanel, an amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-type glutamate receptor antagonist, would treat glioma-related epilepsy. We conducted a single-arm study of adjunctive perampanel for patients with focal-onset glioma-associated seizures. The most common related adverse events were fatigue and dizziness. Three out of 8 participants had self-reported seizure reduction and an additional 3 reported improved control. Of these 6, 5 had isocitrate dehydrogenase 1 mutant gliomas. We conclude that perampanel is safe for patients with glioma-related focal-onset epilepsy. Further study into the association between AMPA signaling, IDH1 status and seizures is warranted.

Full Text

Duke Authors

Cited Authors

  • Dunn-Pirio, AM; Woodring, S; Lipp, E; Herndon, JE; Healy, P; Weant, M; Randazzo, D; Desjardins, A; Friedman, HS; Peters, KB

Published Date

  • 2018

Published In

Volume / Issue

  • 10 /

Start / End Page

  • 114 - 117

PubMed ID

  • 30377587

Pubmed Central ID

  • PMC6202665

International Standard Serial Number (ISSN)

  • 2213-3232

Digital Object Identifier (DOI)

  • 10.1016/j.ebcr.2018.09.003


  • eng

Conference Location

  • United States